TapImmune Inc. (TPIV)

8.34 +0.05 (+0.603%)

IEX Real-Time Price

October 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 8.29

Price Open 8.26

Volume: 100,553

Avg Volume: 241,750

Market Cap: 114.35M

P/E Ratio -

52 Wk Range 2.58-13.55



TPIV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
8.62M
1.11M
4.17
12.86%

2018-09-14
8.62M
1.01M
6.00
11.71%

2018-08-31
8.62M
876,864
6.26
10.17%

2018-08-15
8.62M
837,095
4.30
9.71%




News

TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing (2018-10-17 11:45 PR Newswire)

JACKSONVILLE, Fla. , Oct. 17, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. In connection with the merger, TapImmune Inc. changed its name to Marker Therapeutics, Inc.,…

 


Statistics

Shares Outstanding: 13.71M

Top 15 Institution Percent: 32.40

Price To Sales: 515.16

Price To Book: 25.60

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -160.74

Return On Equity: -227.49

Profit Margin: N/A

Price History

Beta: -0.33

50-day Moving Avg: 8.49

200-day Moving Avg: 5.90

YTD Change: 104.91

5-day Change: 5.84

1-month Change: -12.85

3-month Change: -15.67

6-month Change: 146.75

1-year Change: 163.92

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: TapImmune Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.tapimmune.com

TapImmune Inc is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches.